Categories: AutoimmuneBioTechInflammationPharmaceuticalTherapeutics
Location: United States, California, San Diego
Investors 1
Funding Rounds 1
Mentions in press and media 5
| Date | Title | Description |
| 11.08.2025 | Equillium: Up To $50 Million Financing Raised To Advance EQ504 | Equillium has secured a securities purchase agreement with leading healthcare investors to raise to $50 million. The financing includes an upfront payment of $30 million for approximately 52.6 million shares or pre-funded warrants at $0.57 ... |
| 31.05.2024 | 3 Biotech Stocks Under $20 Worth Watching in June The biotech industry’s long-term expansion is fueled by increasing medical needs globally, favorable government support, and technological advances. G... | - |
| 24.12.2021 | Biocon Ltd. - Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval | Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced that U.S.-based Equillium Inc., Biocon's partner, has expanded its EQUALISE study in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis for It... |
| 11.06.2021 | EQUILLIUM, INC.
Equillium : Announces Positive Topline Results from the EQUATE Studyin First-line Treatment of Acute Graft-Versus-Host Disease (Form 8-K) | Equillium Announces Positive Topline Results from the EQUATE Study
in First-line Treatment of Acute Graft-Versus-Host Disease
Itolizumab continues to demonstrate favorable safety and efficacy profile
Rapid and durable responses resulted in ... |
| 14.11.2018 | Can a 'rediscovered' drug from India make it big in US immunology space? Dan Bradbury and his team at Equillium want to prove yes | Biotech companies typically knock on Nasdaq’s doors with several rounds of financing under their belt. Equillium, however, went straight for it.
Having reaped a $65.4 million IPO last month, the San Diego-based biotech is ... |
Reviews 0
